Utamide 50mg Tablet

Utamide 50mg tablet is a prescription-based anticancer drug with an active ingredient known as Bicalutamide. The doctor prescribes this drug for the treatment of advanced prostate cancer. Utamide 50mg tablet is given as androgen deprivation therapy, a combination of radiation and hormonal therapy. Androgen deprivation therapy drops down the levels of testosterone. The sensitivity of prostate cancer depends on androgen. Hence, the Utamide 50mg tablet aims to lowers the effect of androgen. It is recommended to take proper consultation with your doctor before taking it. Your doctor will decide the dosage and duration of taking the Utamide 50mg tablet. Taking it in the wrong way or overdosing can cause severe side effects. It is advised to use reliable methods of birth control and contraceptive pills to delay pregnancy while under treatment with Utamide 50mg tablet. Discuss with your healthcare expert about the risks and benefits of taking this medicine if you want to conceive in the future. Utamide 50mg tablet is not considered to be safe for pregnant and breastfeeding women, as it may pass through the mother and harm the baby.

Like other anticancer medicines, the Utamide 50mg Tablet has mild to severe side effects. These are undesired symptoms observed in the body after taking this tablet. Usually, they disappear with time as the body adjusts to the medicine. These side effects don't need special medical attention, but if you observe them continually, talk to your medical expert. Some of them are listed below:

Common side effects:
Anemia
Diarrhea
Anxiety
Constipation
Low sex drive
Loss in appetite
Breathlessness
Fall and fractures
Body and back pain
Nausea & Vomiting
Weakness & dizziness
Rashes and skin allergy
Heavy urination during the night

Severe side effects:
Heart problem
blood in urine
Difficulty in urine
Increased blood sugar and liver enzyme level

Utamide 50mg Tablet is a prescription-based anticancer drug that should be administered orally. It is advised to take this tablet after consulting your healthcare expert.

Utamide 50mg Tablet belongs to the drug class of non-steroidal anti-androgens. This medicine binds to cytosol androgen receptors and inhibits the effect of androgen hormones. It blocks the interaction of androgen receptors with testosterone and dihydrotestosterone hormones. In such a way, it shrinks the tumors and slows down the multiplication of the cancer cells.

It is advised not to miss any scheduled dosage of Utamide 50mg Tablet. In case you miss a dose, consult your doctor immediately.
Don't overdose to compensate for the missed one. Contact your doctor or any healthcare provider and seek medical attention immediately in such cases.

Using Utamide 50mg Tablet makes skin sensitive and dry. Use high SPF sunscreen before going out in direct sunlight.
Your healthcare expert must measure your blood sugar & pressure, and liver function tests at regular intervals. Taking the Utamide 50mg Tablet can cause fluctuations in their levels.
It is recommended to inform your doctor if you take any prescribed and non-prescribed medications, nutritional or vitamin supplements, or herbal products. These drugs can interact with Utamide 50mg Tablet and may result in some severe side effects.

Bilusic, M., Toney, N. J., Donahue, R. N., Wroblewski, S., Zibelman, M., Ghatalia, P., & Geynisman, D. M. (2022). A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1). Prostate cancer and prostatic diseases, 25(4), 735-740.
Kotake, T., Usami, M., Isaka, S., Shimazaki, J., Nakano, E., Okuyama, A., & Tsukagoshi, S. (2023). Clinical early phase II study of bicalutamide (Casodex) in patients with prostatic cancer. Hinyokika Kiyo. Acta Urologica Japonica, 42(2), 157-168.
Kunath, F., Grobe, H. R., Ruecker, G., Motschall, E., Antes, G., Dahm, P., & Meerpohl, J. J. (2024). Non‐steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer. Cochrane Database of Systematic Reviews, (6).
Soloway, M. S., Schellhammer, P. F., Joseph Jr., A., Chodak, G. W., Vogelzang, N. J., & Kennealey, G. T. (2025). Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II noncomparative multicenter trial evaluating safety, efficacy, and long-term endocrine effects of monotherapy. The Journal of Urology, 154(6), 2110-2114.
Soloway, M. S., Schellhammer, P. F., Smith, J. A., Chodak, G. W., & Kennealey, G. T. (2022). Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II multicenter trial. Urology, 47(1), 33-37.​